HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- ethylnaphthalen- 1- yl- (1- pentylindol- 3- yl)methanone

a cannabimimetic; structure in first source

Also Known As:

JWH-210

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone: 3
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone: 3
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone: 3

Experts

1.	Angerer, Verena: 1 article (10/2016)
2.	Auwärter, Volker: 1 article (10/2016)
3.	Eyer, Florian: 1 article (10/2016)
4.	Franz, Florian: 1 article (10/2016)
5.	Hermanns-Clausen, Maren: 1 article (10/2016)
6.	Kithinji, Josephine: 1 article (10/2016)
7.	Spehl, Marco: 1 article (10/2016)
8.	Cha, Hye Jin: 1 article (11/2015)
9.	Han, Kyoungmoon: 1 article (11/2015)
10.	Jeong, Ho-Sang: 1 article (11/2015)

Related Diseases

1.	Cognitive Dysfunction 10/01/2013 - "Synthetic cannabinoid testing was performed by LC-MS-MS. Positive results included: JWH-018 (n = 4), 0.1-1.1 ng/mL; JWH-081 (n = 2) qualitative only; JWH-122 (n = 3), 2.5 ng/mL; JWH-210 (n = 4), 0.1 ng/mL; JWH-250 (n = 1), 0.38 ng/mL and AM-2201 (n = 6), 0.43-4.0 ng/mL. While there is good evidence of psychophysical impairment in these subjects, further structured data collection is needed to fully assess the relationship between synthetic cannabinoid use and psychomotor and cognitive impairment. "
2.	Tremor (Tremors) 11/01/2015 - "In functional observation battery (FOB) test, animals treated with 5 mg/kg of JWH-081 or JWH-210 showed traction and tremor. "
3.	Tachycardia (Tachyarrhythmias) 10/01/2016 - "JWH-210 was identified in the serum samples in concentrations ranging from 0.18 to 90 ng/mL. Tachycardia, nausea, somnolence, hypokalemia, hypertension, restlessness, and/or agitation were most frequently reported. "
4.	Seizures (Absence Seizure) 10/01/2016 - "Acute adverse effects of JWH-210 typically include central nervous system depression or cerebral seizures, but also signs of sympathomimetic toxicity. "
5.	Psychomotor Agitation (Akathisia) 10/01/2016 - "JWH-210 was identified in the serum samples in concentrations ranging from 0.18 to 90 ng/mL. Tachycardia, nausea, somnolence, hypokalemia, hypertension, restlessness, and/or agitation were most frequently reported. "

Related Drugs and Biologics

1.	(4- methoxy- 1- naphthalenyl)(1- pentyl- 1H- indol- 3- yl)methanone
2.	Cannabinoids
3.	(4- methyl- 1- naphthyl)- (1- pentylindol- 3- yl)methanone
4.	1-(5-fluoropentyl)-3-(1-naphthoyl)indole
5.	1-(1- pentyl- 1H- indol- 3- yl)- 2- (2- methoxyphenyl)ethanone
6.	1-pentyl-3-(1-naphthoyl)indole
7.	Sympathomimetics (Sympathomimetic Amines)

Related Therapies and Procedures

1.	Traction